A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma

Molecular Cancer Research

Volumn 11, Issue 9, 2013, Pages 1061-1071

  Farley, Megan N ^a,b   Schmidt, Laura S ^e,f   Mester, Jessica L ^g   Peña Llopis, Samuel ^a,b,c   Pavia Jimenez, Andrea ^a,b,c   Christie, Alana ^a   Vocke, Cathy D ^e   Ricketts, Christopher J ^e   Peterson, James ^e   Middelton, Lindsay ^e   Kinch, Lisa ^b   Grishin, Nick ^b   Merino, Maria J ^e   Metwalli, Adam R ^e   Xing, Chao ^c   Xie, Xian Jin ^a   Dahia, Patricia L M ^d   Eng, Charis ^g   Linehan, W Marston ^e   Brugarolas, James ^a,b,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f SAIC FREDERICK INC   (United States)

^g CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 ASSOCIATED PROTEIN 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SUSCEPTIBILITY; ENZYME ACTIVE SITE; FAMILIAL CLEAR CELL RENAL CELL CARCINOMA; FAMILY HISTORY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

ADULT; AGED; AMINO ACID SEQUENCE; CARCINOMA, RENAL CELL; EVOLUTION, MOLECULAR; FEMALE; GERM-LINE MUTATION; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84884497841     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0111     Document Type: Article

References (33)

1. Pavlovich CP, Schmidt LS. Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer 2004;4:381-93. (Pubitemid 38579484)
2. Linehan WM. Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res 2012;22: 2089-100.
3. Malinoc A, Sullivan M, Wiech T, Kurt Werner S, Jilg C, Straeter J, et al. Biallelic inactivation of the SDHC gene in renal carcinoma associated with paraganglioma syndrome type 3. Endo Relat Cancer 2012;19: 283-90.
4. Ricketts CJ, Shuch B, Vocke CD, Metwalli AR, Bratslavsky G, Middelton L, et al. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol 2012;188:2063-71.
5. Eletr ZM, Wilkinson KD. An emerging model for BAP10s role in regulating cell cycle progression. Cell Biochem Biophys 2011; 60:3-11.
6. Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998;16:1097-112. (Pubitemid 28127509)
7. Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, Van Meir EG, et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res 2008;68:6953-62.
8. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011;43:668-72.
9. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010;330:1410-3.
10. Guo G, Gui Y, Gao S, Tang A, Hu X, Huang Y, et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 2012;44:17-9.
11. Peña-Llopis S, Vega-Rubin-de-Celis S, Liao A, Leng N, Pavia-Jimenez A, Wang S, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012;44:751-9.
12. Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavia-Jimenez A, Rathmell WK, et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013;14:159-67.
13. Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, et al. A map of human genome variation from population-scale sequencing. Nature 2010;467:1061-73.
14. Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 2011;48:856-9.
15. Aoude LG, Vajdic CM, Kricker A, Armstrong B, Hayward NK. Prevalence of germline BAP1 mutation in a population-based sample of uveal melanoma cases. Pigment Cell Melanoma Res 2012;26: 278-9
16. Njauw CN, Kim I, Piris A, Gabree M, Taylor M, Lane AM, et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PloS ONE 2012;7:e35295.
17. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011;43:1022-5.
18. Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011;43:1018-21.
19. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-9.
20. Bonne AC, Bodmer D, Schoenmakers EF, van Ravenswaaij CM, Hoogerbrugge N, van Kessel AG. Chromosome 3 translocations and familial renal cell cancer. Curr Mol Med 2004;4:849-54. (Pubitemid 39585730)
21. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004;91:355-8. (Pubitemid 39037083)
22. Barnard GA. Statistical inference. J Royal Stat Society 1949;11: 115-49.
23. Elston RC. 1996 William Allan Award Address. Algorithms and inferences: the challenge of multifactorial diseases. Am J Hum Genet 1997;60:255-62.
24. Hakimi AA, Chen YB, Wren J, Gonen M, Abdel-Wahab O, Heguy A, et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol 2013;63: 848-54.
25. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. PloS ONE 2012;7:e46688.
26. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003;31:3812-4. (Pubitemid 37442253)
27. Misaghi S, Galardy PJ, Meester WJ, Ovaa H, Ploegh HL, Gaudet R. Structure of the ubiquitin hydrolase UCH-L3 complexed with a suicide substrate. J Biol Chem 2005;280:1512-20.
28. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 2006;175:425-31. (Pubitemid 43067318)
29. Wiesner T, Fried I, Ulz P, Stacher E, Popper H, Murali R, et al. Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations. J Clin Oncol 2012;30:e337-40.
30. Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev Cancer 2013;13:153-9.
31. Hoiom V, Edsgard D, Helgadottir H, Eriksson H, All-Ericsson C, Tuominen R, et al. Hereditary uveal melanoma: a report of a germline mutation in BAP1. Genes Chromosomes Cancer 2013;52:378-84.
32. Wadt K, Choi J, Chung JY, Kiilgaard J, Heegaard S, Drzewiecki KT, et al. A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma. Pigment Cell Melanoma Res 2012;25:815-8.
33. Flicek P, Amode MR, Barrell D, Beal K, Brent S, Carvalho-Silva D, et al. Ensembl 2012. Nucleic Acids Res 2012;40:D84-90.